Last reviewed · How we verify
Active Comparator: Morphine
Morphine binds to opioid receptors in the central and peripheral nervous system to produce analgesia and sedation.
Morphine binds to opioid receptors in the central and peripheral nervous system to produce analgesia and sedation. Used for Moderate to severe acute pain, Moderate to severe chronic pain, Cancer pain.
At a glance
| Generic name | Active Comparator: Morphine |
|---|---|
| Sponsor | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Morphine is a mu-opioid receptor agonist that crosses the blood-brain barrier and acts on opioid receptors in the brain, spinal cord, and peripheral tissues. This binding modulates pain perception, reduces anxiety, and produces euphoria. It is one of the oldest and most well-characterized analgesics, commonly used as a reference standard in pain management and opioid research.
Approved indications
- Moderate to severe acute pain
- Moderate to severe chronic pain
- Cancer pain
Common side effects
- Constipation
- Nausea
- Drowsiness
- Dizziness
- Respiratory depression
- Pruritus
- Vomiting
Key clinical trials
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (PHASE3)
- Suicide Preventive Psychosocial Treatment for Youths (NA)
- Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery (PHASE4)
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Lower Body Plyometric Training Effects on Upper Body in Basketball Players (NA)
- Serratus Posterior Superior Intercostal Plane Block (NA)
- Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery (PHASE4)
- Preventing Suicide With Safe Alternatives for Teens and Youths (SAFETY) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: